|
SEC22C expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
9.27569999698008E-08 |
| Normal-vs-Stage3 |
2.50139908786196E-11 |
| Normal-vs-Stage4 |
3.23839843829887E-11 |
| Stage1-vs-Stage2 |
3.062800E-01 |
| Stage1-vs-Stage3 |
9.564000E-01 |
| Stage1-vs-Stage4 |
6.640600E-01 |
| Stage2-vs-Stage3 |
4.412200E-01 |
| Stage2-vs-Stage4 |
2.618400E-01 |
| Stage3-vs-Stage4 |
6.757000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.616600E-04 |
| Normal-vs-Asian |
4.05469999797958E-08 |
| Caucasian-vs-AfricanAmerican |
6.465900E-02 |
| Caucasian-vs-Asian |
2.461600E-01 |
| AfricanAmerican-vs-Asian |
4.425000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.24025267623074E-14 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
4.693400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62481139653892E-12 |
| Normal-vs-Age(41-60Yrs) |
8.52318216004733E-13 |
| Normal-vs-Age(61-80Yrs) |
1.87583282240666E-12 |
| Normal-vs-Age(81-100Yrs) |
9.020300E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.528000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.355000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.940600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.148800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.086800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.929000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.786400E-01 |
| Classical-VS-Follicular |
9.993800E-01 |
| Classical-VS-Other |
3.487800E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
3.675200E-01 |
| Tall-VS-Other |
7.160400E-01 |
| Tall-VS-Normal |
7.4874000333125E-09 |
| Follicular-VS-Other |
4.989600E-01 |
| Follicular-VS-Normal |
9.72739999660632E-09 |
| Other-VS-Normal |
2.979100E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.11652958784725E-14 |
| Normal-vs-N1 |
3.9324099532223E-13 |
| N0-vs-N1 |
3.592100E-02 |
|
|
